Cardiovascular and Metabolic

Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Northeast

Key topics discussed in this specialist interview with a US-based key opinion leader (KOL) include the diagnostic landscape in NASH and future market trends, with a focus on GLP-1 agonists, FGF 19/21 analogs, and FXR agonists.

August 28, 2020

Minimally Invasive Heart Valve Repair and Replacement Devices

This comprehensive medical market and technology report provides an overview and in-depth market analysis of the transcatheter heart valve products used in the treatment of heart valve stenosis, regurgitation, and other valvular disorders.

October 13, 2019

Market Spotlight: Venous Thromboembolism (VTE)

This Market Spotlight report covers the Venous Thromboembolism (VTE) market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, recent events and analyst opinion, probability of success, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.

February 18, 2022

Market Spotlight: Sickle Cell Anemia

This Market Spotlight report covers the Sickle Cell Anemia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals.

March 17, 2022

Market Spotlight: Renal Disease

This Market Spotlight report covers the Renal Disease market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

March 10, 2022

Market Spotlight: Obesity

This Market Spotlight report covers the Obesity market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

March 14, 2022

Market Spotlight: Lysosomal Storage Disorders

This Market Spotlight report covers the Lysosomal Storage Disorders market, comprising epidemiology, key marketed and pipeline drugs, recent events and analyst opinion, key regulatory events, licensing and asset deals, probability of success, and clinical trials.

April 28, 2022

Market Spotlight: Ischemic Stroke

This Market Spotlight report covers the Ischemic Stroke market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, licensing and asset acquisition deals and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.

February 18, 2022

Market Spotlight: Duchenne Muscular Dystrophy (DMD)

This Market Spotlight report covers the Duchenne Muscular Dystrophy (DMD) market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, a 10-year disease prevalence forecast, probability of success, recent events and analyst opinion, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

March 10, 2022

Market Spotlight: Coronary Artery Disease

This Market Spotlight report covers the Coronary Artery Disease (CAD) market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, probability of success, and 10-year disease prevalence and incidence forecasts, as well as presenting drug-specific revenue forecasts.

February 17, 2022

Market Spotlight: Cold Agglutinin Disease

Cold agglutinin disease (CAD) is a clonal B-cell lymphoproliferative disorder and a rare subgroup of autoimmune hemolytic anemia (AIHA). CAD accounts for 15–25% of AIHA and affects mainly middle aged or older individuals. The disease is characterized by the production of autoantibodies by bone marrow-derived clonal B cells which attach to erythrocytes when exposed to cold temperatures (0–4°C), causing agglutination and eventual immune-mediated hemolysis.

February 28, 2022

Market Spotlight: Chemotherapy-Induced Anemia

This Market Spotlight report covers the chemotherapy-induced anemia market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

May 5, 2022

Market Spotlight: Atrial Fibrillation

This Market Spotlight report covers the Atrial Fibrillation market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.

April 7, 2022

Market Spotlight: Amyloidosis

This Market Spotlight report covers the Amyloidosis market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, licensing and acquisition deals, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.

April 14, 2022

Market Spotlight: Acute Decompensated Heart Failure (ADHF)

Approved drugs in the ADHF – preserved ejection fraction (acute HFpEF) space target natriuretic peptide receptors. These drugs are administered via the intravenous route.

March 25, 2022

Ischemic Stroke Market and Forecast Analysis 2024

Stroke is the second most common cause of death and a major cause of disability worldwide. A stroke occurs when there is a blockage or bleed in the cerebrovascular system that leads to either a neurological deficit persisting beyond 24 hours or death.

January 7, 2019

Disease Analysis: Wet Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is the progressive degradation of the part of the eye responsible for visual acuity, causing a loss of central vision. AMD is the leading cause of blindness in individuals who are over 65 years old. As the chances of experiencing any form of AMD increase with age, treatment of this disease is becoming even more important as life expectancies continue to rise in most regions.

January 27, 2022

Disease Analysis: Type 2 Diabetes

Diabetes mellitus is a group of metabolic disorders which are characterized by hyperglycemia (elevated blood glucose levels) due to insufficient insulin secretion, which in type 2 diabetes occurs in the setting of insulin insensitivity.

February 9, 2022

Disease Analysis: Type 1 Diabetes

Diabetes mellitus is a group of chronic endocrine disorders characterized by hyperglycemia due to insufficient levels or action of insulin, a hormone responsible for regulating blood sugar. Symptoms include excessive excretion of urine (polyuria), thirst (polydipsia), constant hunger, weight loss, vision changes, and fatigue. In the long term, the disease can also cause disabling and lifethreatening complications such as cardiovascular disease (CVD), nerve damage (neuropathy, which along with peripheral vascular disease can lead to amputations), kidney damage (nephropathy), and eye disease (leading to retinopathy, loss of vision, and potentially blindness). If untreated, life-threatening conditions can develop, including diabetic ketoacidosis (DKA), particularly in type 1 diabetes, and the hyperosmolar hyperglycemic state in type 2 diabetes

February 10, 2022

Disease Analysis: Pulmonary Hypertension

Pulmonary arterial hypertension is one of a group of rare and life-threatening diseases collectively known as pulmonary hypertension (PH). Each PH subgroup shares similar pathophysiology, clinical presentation, and therapeutic approaches.

November 24, 2021

Disease Analysis: Osteoporosis

Osteoporosis is the most common metabolic bone disease, and is characterized by compromised bone strength which predisposes individuals to an increased risk of fracture. Bone strength itself is not directly measurable, but can be inferred from bone mass and quality, with bone mass being most commonly approximated by assessing bone mineral density (BMD). A person with a BMD measurement that falls within one standard deviation (SD) of the healthy reference (30-year-old male or female) is considered to have healthy bone mass and structure (T-score >-1).

December 23, 2021

Disease Analysis: Non-Alcoholic Steatohepatitis (NASH)

Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of patients who have fatty liver in the absence of significant alcohol consumption. NAFLD patients are often segmented into non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) patients. NAFLD diagnosis requires evidence of hepatic steatosis and lack of secondary causes of liver fat accumulation such as substantial alcohol consumption, long-term use of a steatogenic medicine, or monogenic hereditary disorders. NASH is defined as the presence of >5% hepatic steatosis and inflammation with hepatocyte injury, with or without fibrosis. Although the presence of fibrosis is not required for a diagnosis of NASH, fibrosis is present in over 80% of NASH patients. For this reason, NASH patients are often further segmented by their fibrosis stage.

February 23, 2022

Disease Analysis: Hemophilia

Hemophilia is a rare, inherited X chromosome-linked bleeding disorder in which deficiencies in clotting factors prevent blood from clotting normally. Injuries therefore result in prolonged periods of bleeding. There are two types of hemophilia, A and B, with similar signs and symptoms but different genetic defects.

February 25, 2022

Disease Analysis: Dyslipidemia

Dyslipidemia refers to any increase or decrease in lipid levels from defined normal parameters, with physicians particularly focusing on the treatment of elevated low-density lipoprotein cholesterol (LDL-C) due to the well-established link between excessively elevated LDL-C and atherosclerosis. As such, LDL-C is a major modifiable risk factor for cardiovascular (CV) disease, one of the world’s leading causes of morbidity and mortality, though differences in LDL particle morphology can also play a role. Other lipid level deviations in dyslipidemia include elevated triglycerides, low levels of high-density lipoprotein cholesterol (HDL-C), elevated total cholesterol, and elevated non-HDL-C, a marker of cholesterol in all atherogenic lipoproteins

May 13, 2022

Disease Analysis: Diabetic Nephropathy

Diabetic nephropathy, also known as diabetic kidney disease, is caused by damage to small blood vessels which can cause the kidneys to be less efficient in their blood filtration role or to fail altogether.

March 11, 2022

Disease Analysis: Chronic Heart Failure

Chronic heart failure (CHF) is a progressive condition in which the heart muscle is unable to pump enough blood to meet the needs of the body. CHF can result from functional abnormalities such as ventricular dysfunction or arrhythmias, or structural disorders of the myocardium or valves.

March 31, 2021

Disease Analysis: Anemia in Chronic Kidney Disease

Anemia in chronic kidney disease (CKD), defined as a reduction in red blood cells (RBCs) or hemoglobin levels, often results from decreased levels of erythropoietin and increased levels of hepcidin. Erythropoietin is primarily produced in the kidneys and increases the production of RBCs by acting on precursor cells. H

September 24, 2021

Digital Health: Diabetes Apps and Virtual Coaching

$2,250.00

Smartphone-based digital health technologies are expected to transform the diabetes management market over the next decade by substantially improving diabetes outcomes and reducing healthcare costs. These technologies are engaging and empowering patients, improving glycemic control, and lowering complications. Digital health technologies are defined in this report as: diabetes smartphone apps integrated with blood glucose monitoring devices (both standard blood glucose meters and continuous glucose monitoring systems) and personalized “virtual diabetes coaching” services.

March 10, 2020

Diabetes Management: Insulin Pumps Market (2020)

This report provides an overview of diabetes, automated insulin pump systems, and a comprehensive market and competitive analysis.

December 30, 2020

Diabetes Management: Insulin Pumps Market (2019)

This report provides an overview of diabetes, automated insulin pump systems, and a comprehensive market and competitive analysis.

September 30, 2019

Diabetes Management: Blood Glucose Monitoring Devices Market (2021)

This report provides a detailed presentation of diabetes and blood glucose monitoring devices, including standard fingerstick-based blood glucose meters (BGMs) and new sensor-based continuous glucose monitoring systems (CGMs) that attach to the body and monitor blood glucose 24 hours a day

March 31, 2021

Diabetes Management: Blood Glucose Monitoring Devices Market

According to the International Diabetes Federation (IDF), approximately 425 million adults (20-79 years of age) have diabetes worldwide, and this number is expected to rise nearly 50% to approximately 629 million by 2045. More than 1.25 million people have type 1 diabetes in the US alone.

December 19, 2019

Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Reimbursement

This reimbursement interview with a US key opinion leader (KOL) provides insight into pricing strategies, pricing barriers, and potential reimbursement criteria for non-alcoholic steatohepatitis therapies.

May 20, 2019

Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US

This interview with a US key opinion leader (KOL) provides insight into pipeline therapies for non-alcoholic steatohepatitis (NASH), as well as pricing strategies, diagnostic tools, and future treatment rates for the different fibrosis stages of NASH. Key pipeline assets highlighted include Ocaliva, elafibranor, cenicriviroc, and firsocostat.

May 20, 2019

Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – France

This interview with a French key opinion leader (KOL) provides insight into pipeline therapies for non-alcoholic steatohepatitis (NASH), as well as pricing strategies and future treatment rates for the different fibrosis stages of NASH.

May 20, 2019

2019 Post-ADA Report

$2,995.00

July 22, 2019